Pulsara Around the World - February 2026
January Recap The start of 2026 was on the slow side for our events schedule, with our team heading to the Florida Fire & EMS Conference, the...
1 min read
Brittney Nelson, BSN, RN, SCRN
:
Apr 11, 2017

“I think it will help you as a doctor to know you’re doing a treatment not only for 3 months, but that the treatment benefit is going to last for at least 2 years,” said Yvo Roos, MD. “It’s going to help you be more convincing to the relatives that you’re doing the right thing, that you’re doing something that’s really going to help them."
The above quote is in reference to new long-term followup data published as of April 6th, 2017, which now confirms and extends the outcomes of the MR CLEAN endovascular therapy trial in acute ischemic stroke patients. The results show that 1 out of every 3 patients treated with catheter based intervention are returning home to care for themselves within 3 months and these results are durable up to 2 years! Read the full details of the follow up data right here.
January Recap The start of 2026 was on the slow side for our events schedule, with our team heading to the Florida Fire & EMS Conference, the...
Recent research shows how Pulsara was successfully leveraged to connect more than 6,000 COVID-19 patients to monoclonal antibody infusion centers via...
At Pulsara, it's our privilege to help serve the people who serve people, and we're always excited to see what they're up to. From large-scale...